Fig. 3From: Self-administered subcutaneous medroxyprogesterone acetate for improving contraceptive outcomes: a systematic review and meta-analysisSelf-administration versus provider-administration for continuation of contraceptive use at 12 months. LMIC low middle income countries, HIC high income countriesBack to article page